Advm Stock News

Adverum Biotechnologies Inc (NASDAQ: ADVM) plans to conduct a Phase 2 trial of ADVM-022 in wet AMD at 2 X 10^11 vg/eye dose and a new lower 6 X 10^10 vg/eye dose, with three new enhanced steroid pr

In the last trading session, 1.18 million shares of the Adverum Biotechnologies Inc. (NASDAQ:ADVM) were traded, and its beta was 1.15. Most recently the companys share price was $1.77, and it changed around -$0.09 or -4.84% from the last close, which brings the market valuation of the company to $177.58M. ADVM currently trades at a Adverum Biotechnologies Inc. (NASDAQ: ADVM) Stock: Will It Keep Climbing Higher? Read More »

New Jersey, United States,- Verified Market Research has recently published a research report titled, Hereditary Angioedema Treatment Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to

4 penny stocks with high short interest or low floats to watch this week The post 4 Short Squeeze Penny Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | P

4 penny stocks with high short interest or low floats to watch this week The post 4 Short Squeeze Penny Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | P

Zacks Investment Research upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a hold rating to a buy rating in a research report released on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $2.00 target price on the biotechnology companys stock. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in []

Zacks Investment Research upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning, Zacks.com reports. They currently have $2.00 target price on the biotechnology companys stock. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in []

REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Rupert DSouza, Ph.D., M.B.A., has joined Adverum as the companys chief financial officer (CFO). Dr. DSouza will serve as a member of Adverums executive committee and will report to Laurent Fischer M.D., president and chief executive officer at Adverum Biotechnologies. Dr. DSouza will provide leadership for the companys financial operations and planning, accounting, procurement, and select other functions.

Zacks Investment Research downgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning, Zacks.com reports. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed []

California State Teachers Retirement System cut its position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) by 10.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 119,815 shares of the biotechnology companys stock after selling 14,409 shares during the quarter. California State Teachers Retirement System owned []

Zacks Investment Research upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. The firm currently has $2.25 price objective on the biotechnology companys stock. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and []

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has been assigned an average rating of Hold from the ten brokerages that are presently covering the company, Marketbeat reports. Ten investment analysts have rated the stock with a hold rating. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is []

Adverum Biotechnologies Inc. (NASDAQ:ADVM) shares, rose in value on Friday, 11/26/21, with the stock price down by -4.43% to the previous days close as strong demand from buyers drove the stock to $1.94. Actively observing the price movement in the last trading, the stock closed the session at $2.03, falling within a range of $1.89 Adverum Biotechnologies Inc.s (NASDAQ: ADVM) Future In 2021 Read More »

Zacks Investment Research downgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a buy rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy [] The post Adverum Biotechnologies (NASDAQ:ADVM) Cut to Hold at Zacks Investment Research appeared first on ETF Daily News .

Charles Schwab Investment Management Inc. increased its position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) by 0.9% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 616,913 shares of the biotechnology companys stock after acquiring an additional 5,805 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in Adverum Biotechnologies were worth $2,160,000 as of its []